Description: Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutical and cosmetic-related products; vitamin D products and its analogues; hand and body wash, sanitizers, and antiseptics; and phase transfer catalysts, soft gel capsules, disinfectant formulations, cholesterol, lanolin-related products, and liquid and lyophilized sterile injectables. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Home Page: imdcal.com
Dishman Corporate House
Ahmedabad,
380058
India
Phone:
91 27 1742 0102
Officers
| Name | Title |
|---|---|
| Mr. Arpit Janmejay Vyas | Global MD & Director |
| Ms. Deohooti Janmejay Vyas | Whole Time Director |
| Mr. Harshil R. Dalal | Global Chief Financial Officer |
| Mr. Paolo Armanino | Chief Operating Officer of Indian Operations |
| Ms. Shrima Gaurangbhai Dave | Compliance Officer & Company Secretary |
| Mr. Dharmesh Desai | GM of Secretarial & Legal |
| Mr. Francois Baduel | Vice President of Sales & Marketing |
| Dieter Thuer | Vice President of Human Resources |
| Mr. Pascal Villemagne | Chief Executive Officer of CARBOGEN AMCIS |
| Dr. Himani S. Dhotre | CEO of Projects & Operations |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7372 |
| Price-to-Sales TTM: | 1.6208 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1132 |